XYMBISPHERE Trademark

Trademark Overview


On Thursday, May 12, 2022, a trademark application was filed for XYMBISPHERE with the United States Patent and Trademark Office. The USPTO has given the XYMBISPHERE trademark a serial number of 97408278. The federal status of this trademark filing is SECOND EXTENSION - GRANTED as of Friday, August 9, 2024. This trademark is owned by AstraZeneca AB. The XYMBISPHERE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations and substances for use in oncology; Pharmaceutical preparations and substances for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, neurological, gastrointestinal and immune systems; Pharmaceutical preparations and substances for the treatment of infection, inflammation, hematological, autoimmune related diseases and disorders; Pharmaceutical preparations and substances, namely, antibodies; vaccines
xymbisphere

General Information


Serial Number97408278
Word MarkXYMBISPHERE
Filing DateThursday, May 12, 2022
Status731 - SECOND EXTENSION - GRANTED
Status DateFriday, August 9, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 18, 2023

Trademark Statements


Goods and ServicesPharmaceutical preparations and substances for use in oncology; Pharmaceutical preparations and substances for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, neurological, gastrointestinal and immune systems; Pharmaceutical preparations and substances for the treatment of infection, inflammation, hematological, autoimmune related diseases and disorders; Pharmaceutical preparations and substances, namely, antibodies; vaccines

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, May 17, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAstraZeneca AB
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressSödertälje SE-15185
SE

Party NameAstraZeneca AB
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressSödertälje SE-15185
SE

Trademark Events


Event DateEvent Description
Monday, May 16, 2022NEW APPLICATION ENTERED
Tuesday, May 17, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, December 12, 2022ASSIGNED TO EXAMINER
Friday, December 16, 2022NON-FINAL ACTION WRITTEN
Friday, December 16, 2022NON-FINAL ACTION E-MAILED
Friday, December 16, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, March 3, 2023APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Friday, March 3, 2023APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Monday, June 5, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, June 5, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, June 6, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, June 14, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, June 28, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, July 18, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 18, 2023PUBLISHED FOR OPPOSITION
Tuesday, September 12, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, February 14, 2024SOU EXTENSION 1 FILED
Wednesday, February 14, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, February 14, 2024SOU EXTENSION 1 GRANTED
Thursday, February 15, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, August 9, 2024SOU TEAS EXTENSION RECEIVED
Friday, August 9, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, August 9, 2024SOU EXTENSION 2 FILED
Friday, August 9, 2024SOU EXTENSION 2 GRANTED